NEWTOWN, Pa.--(BUSINESS WIRE)--
Onconova Therapeutics, Inc. (NASDAQ: ONTX) today announced the
appointment of Dr. Jerome Groopman and Anne VanLent to the Board of
Directors.
"I am pleased to welcome Dr. Groopman and Ms. VanLent to Onconova,"
commented Ramesh Kumar, Ph.D., President and Chief Executive Officer of
Onconova. "Jerry's medical and regulatory expertise in
hematology/oncology combined with his familiarity with our programs,
having previously chaired Onconova's Clinical Advisory Board, will be
valuable as we approach important data readouts. Anne brings deep
experience from serving on the boards of publicly-traded life science
companies and will provide oversight as the Chair of our audit
committee. Our board looks forward to working with them."
Dr. Groopman has served as the Dina and Raphael Recanati Professor of
Medicine at Harvard Medical School since January 1992. He has also
served as Attending Hematologist/Oncologist at Beth Israel Deaconess
Medical Center since July 1996. Dr. Groopman received a M.D. from
Columbia University College of Physicians and Surgeons, and a B.A. in
Political Philosophy from Columbia College.
Ms. VanLent has served as President of AMV Advisors, a personal
consulting firm providing strategic and financial services to companies
in the greater life sciences sector, since May 2008. Ms. VanLent has
also served as a director and chair of the audit committee of Biota
Pharmaceuticals, Inc. since May 2013, Aegerion Pharmaceuticals, Inc.
since April 2013 and Ocera Therapeutics, Inc. since March 2011. From
December 2004 to May 2013, Ms. VanLent was a director of Integra Life
Sciences Holding Corporation, serving as a member of the audit committee
from December 2004 to May 2013 and as its chair from May 2006 to May
2012, as well as serving as a member of the compensation committee from
2005 to 2006. From 1998 to 2010, Ms. VanLent served as a director of
Penwest Pharmaceuticals Co., where she was chair of the audit committee
between 1999 and 2010 as well as chair of the nomination and governance
committee from 2008 to 2010. Ms. VanLent received a B.A. degree in
Physics from Mount Holyoke College.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company
focused on discovering and developing novel products to treat cancer.
Onconova's clinical and pre-clinical stage drug development candidates
are derived from its extensive chemical library and are designed to work
against specific cellular pathways that are important in cancer cells,
while causing minimal damage to normal cells. In addition to rigosertib,
the Company's most advanced product candidate, two other candidates are
in clinical trials, and several candidates are in pre-clinical stages.
For more information, please visit http://www.onconova.com.
Onconova Therapeutics
Benjamin Hoffman, 267-759-3680
bhoffman@onconova.us
or
Media:
MacDougall
Biomedical Communications
Doug MacDougall, 781-235-3060
dmacdougall@macbiocom.com
Source: Onconova Therapeutics, Inc.
News Provided by Acquire Media
